Latest:
Dr Ecker on the Role of CAPETEM in the Treatment of Pancreatic NETs
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Nagi S. El-Saghir, MD, FACP, FASCO
Nagi S. El-Saghir, MD, FACP, FASCO is Professor of Clinical Medicine, Head of the Division of Hematology Oncology, Department of Internal Medicine and Director of the Breast Center of Excellence, Naef K Basile Cancer Institute, American University of Beirut Medical Center, Beirut, Lebanon.
Latest:
Dr El-Saghir on the Investigation of Ribociclib Plus ET in HR+, HER2– Advanced Breast Cancer
Nagi S. El-Saghir, MD, FACP, FASCO, discusses the inception of the phase 2 RIGHT Choice trial of ribociclib plus ET.
Mohamed Abdelbaki, MD
Mohamed Abdelbaki, MD, is a professor of pediatrics and director of the Pediatric Neuro-Oncology Program both at the University of Washington School of Medicine in St Louis.
Latest:
Dr Abdelbaki on Second-Line Targeted Therapy in BRAF+ Pediatric Low-Grade Glioma
Mohamed Abdelbaki, MD, discusses second-line targeted therapy options for pediatric low-grade glioma.
Elizabeth Shaughnessy, MD, PhD
Latest:
Women in Oncology: Self-Advocacy in a Busy Field
Melinda Butsch Kovacic, MPH, PhD; Elizabeth Shaughnessy, MD, PhD; Sandra L. Starnes, MD; and Susan E. Waltz, PhD, discuss the advice they would give to their younger selves and future female oncology professionals, knowing what they know now about the oncology field and their own career growth.
Patrick Y. Wen, MD
Patrick Y. Wen, MD, is is the director of the Center for Neuro-Oncology at Dana-Farber Cancer Institute; as well as a professor of neurology at Harvard Medical School
Latest:
Future Research Directions in Primary CNS Tumors
Patrick Y. Wen, MD, and Karisa C. Schreck, MD, PhD, discuss potential directions for future research in primary central nervous system malignancies.
Nuhad K. Ibrahim, MD
Latest:
Dr Ibrahim on the Study of Eftilagimod Alpha Plus Paclitaxel in HER2-Negative or -Low Breast Cancer
Nuhad K. Ibrahim, MD, discusses the investigation of eftilagimod alpha plus in hormone receptor–positive HER2-negative or HER2-low metastatic breast cancer in the phase 3 AIPAC-003 trial.